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a b s t r a c t
One of the hallmarks of malignant cell populations is the ability to undergo continuous proliferation. This
property allows clonal lineages to acquire sequential aberrations that can fuel increasingly autonomous
growth, invasiveness, and therapeutic resistance. Innate cellular mechanisms have evolved to regulate
replicative potential as a hedge against malignant progression. When activated in the absence of normal
terminal differentiation cues, these mechanisms can result in a state of persistent cytostasis. This state,
termed “senescence,” can be triggered by intrinsic cellular processes such as telomere dysfunction and
oncogene expression, and by exogenous factors such as DNA damaging agents or oxidative environments.
Despite differences in upstream signaling, senescence often involves convergent interdependent activation of tumor suppressors p53 and p16/pRB, but can be induced, albeit with reduced sensitivity, when
these suppressors are compromised. Doses of conventional genotoxic drugs required to achieve cancer
cell senescence are often much lower than doses required to achieve outright cell death. Additional therapies, such as those targeting cyclin dependent kinases or components of the PI3K signaling pathway, may
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induce senescence speciﬁcally in cancer cells by circumventing defects in tumor suppressor pathways
or exploiting cancer cells’ heightened requirements for telomerase. Such treatments sufﬁcient to induce
cancer cell senescence could provide increased patient survival with fewer and less severe side effects
than conventional cytotoxic regimens. This positive aspect is countered by important caveats regarding
senescence reversibility, genomic instability, and paracrine effects that may increase heterogeneity and
adaptive resistance of surviving cancer cells. Nevertheless, agents that effectively disrupt replicative
immortality will likely be valuable components of new combinatorial approaches to cancer therapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction

2.1. Telomerase repression

Among the notable feats of evolution is the remarkable protection from cancer that is enjoyed by long-lived species such
as humans. Despite billions of cell divisions and trillions of cells,
humans remain, on average, cancer-free for more than 50 years.
One of nature’s notable tumor suppressive mechanisms is cellular
senescence, a response to nonlethal stress that results in persistent
cytostasis. In the absence of normal growth arrest accompanying differentiation, senescence imposes limits on the proliferative
capacity of clonal cell lineages. Senescence can be induced by multiple stimuli, including intrinsic cellular processes such as telomere
dysfunction and oncogene expression, but also by exogenous factors such as DNA damaging agents or oxidative environments.
Abundant published evidence now supports the concept that
senescence is a signiﬁcant impediment to malignancy, and that it
is ordinarily very stringent. Indeed, as a number of investigations
have shown, many cell types in which one or more senescence pathway components are functionally inactivated remain susceptible to
senescence – an indication that robust compensatory mechanisms
exist for this important stress response. Despite the resiliency of
the senescence response, however, it is prone to failure to varying degrees, depending upon genetic/epigenetic context. Failure
of senescence in cells that have undergone oncogene activation,
telomere dysfunction, and/or DNA damage can result in changes
favoring malignancy and drug resistance. Elucidation of mechanisms that enforce senescence has been sought in expectation that
such knowledge should lead to measures that prevent or reverse
its failure in susceptible pre-malignant and malignant cell populations. In this review, we focus on telomeres and other mediators of
senescence induction as candidate targets for the prevention and
treatment of cancers.

In the absence of externally or oncogenically induced stresses,
telomerase repression may be the only physiological impediment to indeﬁnite replication. Replicative senescence, as originally
described by Hayﬂick in cultures of cells from non-malignant tissues, is due to natural repression of telomerase and the resulting
DNA damage response that occurs when the number of telomeric
TTAGGG repeat sequences on the ends of chromosomes becomes
too few to support the assembly of stable telomere complexes
[1,2]. Structures formed through interactions of TTAGGG repeat
sequences with a protein complex referred to as shelterin function
to “cap” the chromosome ends, protecting against DNA degradation, recombination, and chromosome fusion [3]. The telomeric
TTAGGG repeats are replenished by telomerase [4], a ribonucleoprotein complex that consists of a catalytic reverse transcriptase
protein subunit (hTERT, TERT) [5–7], an RNA template (hTR, TERC)
[8–10], and other accessory proteins, including the RNA-modifying
protein dyskerin [11,12]. The presence of hTERT and hTR are the
minimum requirements for recapitulation of telomerase activity
in vitro. Telomerase activity and telomere length elongation in cancer are associated with up-regulation of both hTR and hTERT, while
overexpression of hTR has been shown to boost telomerase activity and more dramatically extend telomere length in cells that
express endogenous or ectopic hTERT [13–15]. Thus both telomerase components restrict telomerase activity and telomere length
in vitro, illustrating the fact that both components are required
for a functional telomerase holoenzyme. Although hTERT was initially considered as the limiting component of telomerase, evidence
from biochemistry, promoter studies, mouse models, and human
tumors has demonstrated contexts where hTR limits telomerase
enzyme levels and telomere maintenance [13–18]. At early embryonic stages, the hTERT gene and telomerase activity are expressed
at high levels in many tissues [19,20]. The hTERT gene then undergoes repression as embryonic cells differentiate into adult somatic
cells [21]. From the neonatal period onward, hTERT transcripts
and telomerase activity are nearly or completely undetectable in
most human tissues [19,22,23], except in some highly proliferative tissues, such as lymphoid cells and tissue stem and progenitor
cells [24–27]. In vitro, attrition of TTAGGG repeats upon successive
divisions in cells lacking sufﬁcient telomerase activity ultimately
results in DNA damage responses including growth arrest, followed
by cell enlargement, chromatin condensation, and vacuolization
– characteristic features of senescent cells. Multiple and distinct
human cancer precursor lesions, but not corresponding malignant cancers, are composed of cells that display signs of telomere
dysfunction-induced senescence [28]. Ectopic hTERT expression in
many cell types prevents these senescent changes by stabilizing
telomeres and extending replicative lifespan [29–32]. While not
intrinsically essential for malignancy [33], an extended lifespan or
“immortalization” permits clonal cell lineages to accumulate rare
genetic and epigenetic aberrations that together can cause malignant transformation.
In the absence of a telomere maintenance mechanism, telomeres shorten with each round of cellular replication to eventually

2. Causes of senescence
Proliferating cells can respond to genotoxic and non-genotoxic
stresses in a number of ways, including transient cell-cycle arrest,
senescence, and cell death. Senescence is operationally broadly
deﬁned as a viable growth arrest characterized by the inability
of affected cells to resume proliferation in the presence of appropriate mitogenic factors. While multiple cellular and molecular
features, including increased cell size, accumulation of lysosomes,
upregulation of cell cycle inhibitors, presence of senescenceassociated heterochromatic foci (SAHF), and positive staining for
senescence-associated beta-galactosidase (SA-␤Gal) activity, have
been associated with senescent cells, no single feature is a universal and speciﬁc marker of senescence. Experimental and clinical
evidence indicate that an intact senescence response is important
for preventing unregulated growth and malignant transformation.
In addition, the ability to undergo senescence can determine the
efﬁcacy of targeted cancer therapies. As described below, however,
senescence is not a discrete mechanism or pathway that can be easily classiﬁed as either intact or entirely non-functional. Instead, it is
a process that can result from many different inputs with degrees
of sensitivity dictated by intrinsic as well as extrinsic factors.
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reach critically short lengths that are unable to support stable
formation of shelterin protein complexes that protect telomeres
from DNA damage surveillance mechanisms [34]. In normal cells,
dysfunctional telomeres and abnormal chromosomal structures
initiate a p53-mediated DNA damage response [35]. The p16/pRB
tumor suppressor pathway is also activated during replicative
senescence in response to telomere dysfunction and DNA damage [36,37]. Activation of these tumor suppressors halts cell cycle
progression, initiates senescence, and prevents the propagation of
abnormal chromosomes. However, genetic or epigenetic aberrations in p53 and/or p16/pRB pathways enable otherwise normal
cells to continue to proliferate. Cells that bypass senescence as
a result of defects in these pathways are subject to continued
telomere shortening and telomere dysfunction with consequential
evolution of complex karyotypes [38–40]. Critically short telomeres
are fusogenic, resulting in formation of unstable structures, such
as dicentric and ring chromosomes [38,41]. Continued telomere
dysfunction promotes the development of abnormal chromosomes
through breakage-fusion-bridge (BFB) cycles, which are initiated by
fused chromatids [40,42]. During BFB cycles, fused chromatids form
bridges during anaphase. Chromatin bridges break as cells continue through mitosis, resulting in uneven segregation of genetic
material and unstable chromosome structures, which fuel further
BFB events in daughter cells. BFB cycles continue until abnormal chromosome structures are lost or stabilized [43]. Resulting
chromosome abnormalities include non-reciprocal translocations,
deletions, gene ampliﬁcations, and whole chromosome losses [43].
These types of chromosomal aberrations have been demonstrated
in association with telomere dysfunction in cell culture models,
p53-null mice, tumor-derived cell lines, and pre-malignant conditions [38,40,42,44–49]. They are also the hallmarks of human
carcinomas that feature chromosomal instability [46,50–54]. By
accelerating the rate and accumulation of molecular changes, telomere dysfunction-driven chromosomal instability may result in
activation of telomerase, activation of oncogenes and/or silencing
of tumor suppressor genes, which ultimately cooperate to promote
malignant transformation, tumor progression, and drug resistance
[44–48,52,54,55].
2.2. Oncogenic stress
In contrast to replicative senescence, oncogene-induced senescence (OIS) often occurs independently of telomere status [56,57],
but shares many of the same morphological and biochemical
features [36,58–61]. OIS is observed after ectopic expression of
oncogenic RAS, and many of its effectors, including activated
mutants of RAF, MEK, B-RAF, PI3K, AKT, and PIM [62–66], and
other oncogenes such as CDC6, cyclin E and STAT5 [67]. Also, functional abrogation of tumor suppressors such as PTEN, pRB, Spn,
and NF1, induces senescence-like responses [68]. Stress associated
with aberrant DNA replication caused by these oncogenic changes
appears involved in OIS [69–72]. Although the mechanism is not
fully understood, it may be due to increased expression of positive
regulators of S-phase. Consequently, replicons reﬁre or terminate
prematurely, generating DNA breaks that initiate a DNA damage
response and phosphorylation of p53 by DNA damage response
kinases. Components of the MAPK cascade also increase the expression of the tumor suppressor ARF [73], and initiate a negative
feedback loop that ultimately inhibits H/MDM2 [65], resulting in
p53 stabilization.
The presence of senescent cells induced by oncogenic signaling
has been documented in several precancerous tissues of both
human and mouse, indicating that OIS occurs in vivo [74–78]. The
ﬁrst direct evidence of cellular senescence in a growth-arrested
human neoplasm was reported in benign human melanocytic nevi
(moles) [77]. Cells in nevi carry an activated oncogene product

(B-Raf-E600), express elevated levels of the tumor suppressor p16,
undergo long-term cell-cycle arrest, and display abundant SA-␤Gal activity. In addition, they do not show detectable signs of
telomere erosion, suggesting that they have undergone OIS rather
than replicative senescence. These and similar results reported by
others [79] suggest that OIS in nevi acts as a barrier to melanoma
development.
2.3. External agent-induced stress
Conventional genotoxic radiotherapy and chemotherapeutic
regimens are potent inducers of senescence in cancer cells in vitro
and in vivo (reviewed in [80]). Although this senescence response
has been shown to involve many of the same DNA damage
response mediators (e.g., ATM, ATR, Chk1, Chk2) as those activated by telomere dysfunction and oncogene activation, it is
noteworthy therapeutically that cancer cells lacking functional
tumor suppressors such as p53 or pRB often retain the capacity to undergo external agent-induced senescence. While in some
cases, senescence-inducing drugs clearly act through the generation of DNA damage, in other cases the mechanisms involve only
alterations in DNA structure and function (e.g., inhibition of DNA
methylation or histone acetylation). Still other compounds may
induce senescence through direct or indirect stimulation of stress
sensitive kinases, creating imbalances in mitogen signaling pathways [81].
The chief clinical advantage of targeting senescence rather than
outright cell death as a desired endpoint is that drug doses required
to achieve cancer cell senescence are often much lower than doses
required to achieve outright cell death. In prostate cancer cell lines,
for example, a dose of 25 nM doxorubicin is sufﬁcient to induce
senescence, while doses >250 nM are necessary to cause cell death
[82]. In practical terms, treatment with lower doses of genotoxic
drugs that are sufﬁcient to induce senescence but not cell death
could provide equivalent or prolonged patient survival with fewer
and less severe side effects. There are caveats to this approach, however, as mentioned elsewhere in this review. Chief among them
are the questions of senescence reversibility and pro-tumorigenic
paracrine effects of senescent cells that are not cleared by the
immune system.
3. Mediators of senescence
Gene expression proﬁling has revealed that there is limited
overlap among genes exhibiting altered expression in cells induced
to undergo senescence by telomere shortening, oncogene induction, or external agents [83–88]. The data indicate that fundamental
differences exist in gene regulation during senescence activated
by various signals in different cell types, despite similarity in the
resulting phenotypes. Despite differences in upstream signaling,
however, induction of senescence often involves convergent interdependent activation of tumor suppressors p53 and p16, the former
protein initiating and the latter maintaining the response [89,90].
While this sequence is demonstrable in lymphoma cells exposed
to cyclophosphamide [91] and ﬁbroblasts exposed to activated
Ras [59], in other cases, such as human mammary epithelial cells
exposed to suboptimal culture conditions [48,92] and melanocytes
which acquire B-RAF mutations [93], p16 activation and senescence occur independently of p53 activation. Although p53 and p16
are clearly involved in establishing senescence growth arrest, their
precise roles in this process are incompletely understood.
3.1. p53
The importance of p53 in senescence was determined by inhibiting p53 function with dominant negative mutants, speciﬁc p53
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antisense mRNA, oligonucleotides or viral oncoproteins (such as
SV40 T antigen or HPV16 E6); such treatments were sufﬁcient
to substantially extend the lifespan of several cell types in culture [94]. Consistent with these ﬁndings, senescence is associated
with the transactivation of p53 in cultured cells [95]. Coincident
with telomere shortening and DNA-damage checkpoint activation,
p53 is also activated in vivo [45]. Deletion of p53 attenuated the
cellular and organismal effects of telomere dysfunction [45,96].
Proteins that regulate p53 have also been implicated in senescence.
MDM2 has p53 ubiquitin ligase activity and forms an autoregulatory loop with p53 [97]. Overexpression of MDM2 targets p53
for degradation and induces functional p53 depletion [98]. Expression of another factor upregulated in senescence, ARF, can release
p53 from MDM2 inhibition and cause growth arrest in young
ﬁbroblasts [98]. Seeding mouse embryonic ﬁbroblasts (MEFs) into
culture induces ARF synthesis, which continues to accumulate until
the cells enter senescence [99]. MEFs derived from ARF-disrupted
mice [99] or wild type ﬁbroblasts expressing an ARF antisense
construct [100] are efﬁciently immortalized. Consistent with this
observation, overexpression of MDM2 in MEFs produces efﬁcient
immortalization [100].
Senescence effects of p53 are mediated in part through
increased expression of the CDK inhibitor p21WAF1 [101–103]. p21,
in turn, prevents hyperphosphorylation and inactivation of pRB
[104,105]. In some human cells, elimination of p21 is sufﬁcient
to bypass senescence [101]. However, in MEFs, the absence of
p21 does not prevent senescence [106,107]. This ﬁnding indicates
that at least one additional downstream effector can independently mediate p53-induced senescence. Candidate p53 effectors
include 14-3-3 and GADD45, which inhibit G2/M transition, or p53dependent transcriptional repression of c-Myc, which results in G1
cell cycle arrest [108]. Other signals may cooperate with p53 to
induce senescence. For example, Ras-induced activation of PPP1CA,
the catalytic subunit of PP1␣, has been shown to be necessary for
Ras-dependent senescence [109]. Independently of p53, PPP1CA
can stabilize the active unphosphorylated form of pRB. In MEFs,
E2F transcription factor associated repressor complexes are downstream targets of p53-induced proliferation arrest [110], indicating
a convergence of the p53 and p16/pRB pathways at the level of E2F.
However, in many human cells, inactivation of either p53 or pRB
(e.g., by viral oncoproteins or anti-sense oligonucleotides) independently and synergistically extends replicative life span [111–113].
These ﬁndings suggest that although the p53 and pRB pathways
interact, they may also act separately to establish senescence.
3.2. p16/pRB
While the causes of p16 induction remain to be deﬁned, its
mechanism of action has been well characterized. The binding of
p16 to cyclin dependent kinases (CDKs) 4 and 6 induces allosteric
conformational changes that disrupt the interaction of these
kinases with D-type cyclins [114], thus antagonizing activation
of the CDKs. Through binding and inactivation of CDKs, p16 prevents phosphorylation and inactivation of pRB and similar “pocket”
proteins, p107 and p130. This canonical description, while valid,
obscures the differences in RB family functions that distinguish
reversible cell cycle arrest from irreversible senescence-associated
changes. Despite the similarities among RB family proteins, defects
in pRB, but not in p107 or p130, have been associated with human
cancers. This suggests that pRB has unique tumor suppressor properties not attributable to p107 or p130. In support of this concept,
pRB has been shown to be preferentially associated with E2F targets involved in DNA replication during OIS, and suppression of
pRB, but not p107 or p130, allowed continued DNA synthesis after
induction of oncogenic RAS [115]. The pRB protein contains multiple phosphorylation sites and interacts with multiple protein
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Fig. 1. A simpliﬁed scheme is presented of hypothetical alternative phosphorylation states and growth arrest functions of RB family proteins. Gray circles represent
phosphate groups added to RB family proteins by different cyclin-CDK complexes.
The primary sites of action of endogenous CDK inhibitors, p16 and p21, as well as
the small molecule inhibitor, PD0332991, are also shown.

complexes. It remains to be determined whether the spectrum of
pRB dependent changes in a given cell type under speciﬁc conditions is simply determined by the duration of pRB activation or
by qualitative differences in pRB modiﬁcations/binding interactions. Changes initiated by p16 expression are qualitatively and
quantitatively distinct from those in cells undergoing transient
pRB-dependent growth arrest. For example, in U2OS cells exposed
to p16, pRB augments p130 at E2F-regulated promoters. Dean
and co-workers [116] used chromatin immunoprecipitation (ChIP)
assays to assess protein association with the E2F responsive cyclin
E and A promoters. A 6-day induction of p16 resulted in a dramatic
increase in pRB and E2F-4 associated with these promoters. Additional promoter-speciﬁc changes in the extent of binding to histone
deacetylase HDAC1, SWI/SNF chromatin remodeling complex components BRG1 and Brm, and polycomb group protein HPC2 were
noted.
Distinctions in pRB-associated phenotypes may be due to differences in the functionality of different phosphorylated forms of
pRB (Fig. 1). Although growth factors are required for cyclin D1
synthesis, transiently growth-arrested cells often contain signiﬁcant amounts of cyclin D3 associated with CDK4, and the level of
CDK4 activity is sufﬁcient for cell cycle progression if CDK inhibitors
are removed [117]. Thus in transiently growth-arrested cells, pRB
may be held preferentially in a hypophosphorylated rather than an
unphosphorylated state. While many past studies have relied on
the effect of hyperphosphorylation on the electrophoretic mobility
of pRB to distinguish the hyperphosphorylated from the hypophosphorylated form, few have distinguished the unphosphorylated
from the hypophosphorylated form [118]. E2Fs are more easily
co-immunoprecipitated with the hypophosphorylated form of pRB
than the unphosphorylated form of pRB in peripheral blood lymphocytes (PBLs) during early G1 [119]. Interestingly, transduction
of p16 protein into PBLs leads to loss of pRB hypophosphorylation and loss of detectable pRB association with E2F-4. The lack
of detectable association might be due to reduced afﬁnity of the
unphosphorylated form of pRB for E2F-4, or alternatively to relative insolubility of larger chromatin complexes containing both
pRB and E2F-4. Regardless of the interpretation, the results suggest
that pRB maintained in a minimally or completely unphosphorylated state in the presence of p16, is likely to have properties
that differ from those of the hypophosphorylated form. Conﬁrmation of this concept is apparent in the results of an expression
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proﬁling study of rat ﬁbroblast cell lines [120]. In this study, the
effects on global gene expression of a pRB allele refractory to cyclinCDK phosphorylation (the presumed state of pRB in the presence of
p16) were compared to those of E2F-2 overexpression. The targets
of unphosphorylated pRB were consistent with genes downregulated by p16 overexpression, but showed lower correspondence to
genes stimulated by E2F-2. Similar results using human U2OS cells
were reported [121].
3.3. pRB-mediated heterochromatin formation during cellular
senescence
pRB can play an active role in the formation of senescenceinduced heterochromatic foci (SAHF) in human cells. Originally
characterized in senescent ﬁbroblasts [122], these foci consist of
reorganized DNA and are enriched for proteins normally associated
with heterochromatin, such as histone H3 methylated on lysine 9
(H3-K9Me), and heterochromatin protein 1 (HP1) proteins ␣, ␤, and
␥. The formation of SAHF was slow, taking several days or weeks,
depending on the initiating stimulus, and was reported to coincide with the enhanced association of E2F-target promoters with
heterochromatin proteins. Notably, these changes were blocked by
expression of the adenoviral E1A protein, which inactivates pRB
and prevents senescence. Interestingly, senescent BJ ﬁbroblasts,
which poorly express p16 and were less stably arrested [122], displayed fewer SAHFs than senescent ﬁbroblasts that express higher
amounts of p16 [123].
The chromatin-based role of pRB in transcriptional repression
is complicated, with multiple factors cooperating for transcriptional repression of speciﬁc promoters. For example, repression of
cyclin A has been shown to be dependent on SWI/SNF chromatin
remodeling, whereas other forms of transcriptional repression have
been shown to be dependent on histone deacetylases or polycomb
repressor components [116,124–126]. In addition to the E2Fs, pRB
can also associate with HP1 and histone methyltransferases such
as SUV3-9H1, raising the possibility that pRB helps direct the process of histone methylation and HP1 recruitment to E2F responsive
promoters during senescence. Consistent with this possibility, pRB
showed colocalization with SAHFs in the nuclei of senescent cells,
which was greater than that observed for p107 and p130 [122].
Additional work [127] has shown that p16-dependent repression
by pRB at E2F target gene promoters involves the establishment
of a stable repressor complex that is not displaced by the overexpression of E2F-1. Rather than displacing pRB, excess E2F-1 instead
recruits more pRB, leading to direct transcriptional repression. In
contrast, Rb family members, p130 and p107, which have not been
demonstrated to be tumor suppressors, bind preferentially to target promoters in the absence of growth factors and in proliferating
cells, respectively, and these repressor complexes are displaceable
by E2F-1. HP1, which interacts with pRB, is associated with these
distinct repressor complexes and follows a similar pattern of stability/displaceability. Efﬁcient growth arrest by p16/pRB in MEFs is
dependent on H3-K9Me, which provides a binding site for HP1. Differences in the stability of repressor complexes at promoters may
underlie the different roles of pRB versus p130 and p107 in cell cycle
regulation and tumor suppression [127].
Although the mechanisms responsible for formation and propagation of heterochromatin remain to be characterized, H3-K9Me,
trimethylation of histone H4 lysine 20 (H4-K20Me), and recruitment of HP1 appear to be involved [128,129]. Trimethylation of
heterochromatic histone H3-K9 is accomplished by Suv3-9H1 and
Suv3-9H2 [130], while Suv4-20H1 and Suv4-20H2 trimethylate
histone H4-K20 [129]. pRB physically interacts with both these
methyltransferase complexes, although the biological signiﬁcance
of these interactions remains unclear [131,132]. Importantly, H3K9Me was enriched at proliferation-associated gene promoters

speciﬁcally in senescent cells, concomitant with the appearance of
SAHFs, but not in quiescent cells [122]. In addition, Suv3-9, which is
responsible for H3-K9Me, has been found to be required for OIS in
murine lymphocyes, and for suppression of lymphoma [64]. Therefore senescent cells are thought to maintain growth arrest through
the formation of heterochromatin at proliferation-promoting gene
loci.
Molecular details of SAHF formation and stability remain to
be determined. In addition to pRB, H3-K9Me, and HP1, SAHFs
are known to be enriched in a histone H2A variant, macroH2A,
previously associated with silenced chromatin [133], and HMGA
proteins, which appear to be essential for SAHF formation [123].
Two evolutionarily conserved histone chaperones, HIRA and ASF1a,
are also known to cooperate with pRB in the formation of SAHFs
[134]. These proteins, human orthologs of proteins known to create transcriptionally silent heterochromatin in yeast, ﬂies, and
plants, may generate more extensive heterochromatin domains at
positions designated by pRB. In WI38 human ﬁbroblasts induced
to undergo senescence by the introduction of an activated Ras
oncogene, each chromosome condenses into a single SAHF focus
[135]. The chromosome condensation is hypothesized to depend,
in part, on increased nucleosome density due to HIRA/ASF1amediated nucleosome deposition. This chromatin condensation
occurs prior to the accumulation of H3-K9Me and deposition of
HP1 and macroH2A in chromatin, leading to speculation that HP1
proteins do not contribute to the acute onset of the senescent phenotype, but that instead, they might be required for the long-term
maintenance of SAHF and the senescent state. Similarly, recent
work using the same inducible OIS model has shown that the global
pattern of repressive histone marks was largely unchanged during
senescence, indicating that SAHF formation largely involves repositioning of chromatin bearing pre-existing marks rather than de
novo formation of new marks [136]. This work also showed that
H3-K9Me and H3-K27Me marks were not necessary for SAHF formation. However, the contribution of these individual components
to senescence irreversibility remains to be determined.

4. Evidence that senescence is tumor suppressive
A protective role of senescence has been inferred in murine
models of lung adenomas, T-cell lymphomas, prostate tumors, and
pituitary tumors [74–76,78]. In one example, Ras-V12 knock-in
mice were shown to develop lung adenomas that were characterized by low proliferative indices, elevation of SA-␤-Gal activity, and
other senescence markers [137]. By contrast, the few adenocarcinomas that did emerge showed considerable proliferative activity and
lacked senescence markers. In another example, Ras-V12-driven
mouse T-cell lymphoma cells in which apoptosis was blocked
entered senescence after drug therapy, and senescence was shown
to be dependent on the chromatin-remodeling enzyme Suv3-9H1
[74]. In another study, p53 and p16 were found to cooperate in
murine lymphoma cells, engaging a program of prolonged cellcycle arrest in response to the alkylating agent, cyclophosphamide
[91]. Mice bearing tumors capable of p16-induced senescence had
a much better prognosis following chemotherapy than those harboring tumors with p16 defects. The study showed further that p16
loss and disruption of apoptosis by Bcl2 act independently to promote drug resistance. In a prostate tumor model, p53-dependent
cellular senescence could be triggered by inactivation of the tumor
suppressor, PTEN [75]. Similar ﬁndings have been reported in E2F-3
driven pituitary gland tumors [138].
Direct evidence that senescence is tumor suppressive has been
generated using inducible murine models. In a model for p53dependent liver cancer, the effect of p53 restoration was studied
in established liver carcinomas [139]. Hepatoblasts expressing
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a conditional p53 shRNA produced invasive hepatocarcinomas.
Soon after re-expression of p53, the tumors underwent dramatic
regression associated with cellular senescence. The senescent cells
acquired a speciﬁc gene expression proﬁle that included upregulation of inﬂammatory cytokines; this led to activation of the innate
immune system, which was responsible for clearing the tumor. This
work established a link between the cellular senescence program
and the innate immune system in suppressing tumorigenesis. Similar work by others using a mouse osteosarcoma model has also
shown that re-expression of endogenous p53 leads to a senescencelike cell-cycle arrest and complete tumor regression [140].
Correlative data indicate that stress-induced senescence is
tumor suppressive in human tissues as well. In malignant
cells, senescence is a well-documented consequence of various
chemotherapeutic regimens [80]. In a speciﬁc example in which
SA-␤gal activity was used as a marker of senescence, 15/36 breast
tumor resections after neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, and 5-ﬂuorouracil) were found positive for
SA-␤gal, while only 2/20 untreated tumors showed any SA-␤gal
staining, suggesting that the induction of senescence may be favorably related to treatment outcome [141]. The senescence response
was associated with those tumors bearing wild-type p53 alleles
and exhibiting p16 expression. Interestingly, the normal tissue of
chemotherapy-treated patients was completely negative for SA␤gal, indicating potential selectivity in the senescence response.
Similar observations have been made in lung tumors resected from
patients receiving neoadjuvant chemotherapy [142].

5. Evidence that senescence can promote malignancy – the
senescence associated secretory phenotype
Unlike cells that are removed by other tumor suppressor
mechanisms such as programmed cell death, senescent cells can
persist and continue to actively interact with surrounding cells
and tissues for extended periods of time. Defective elimination
of senescent cells may lead to unregulated accumulation in aging
tissues and at sites of age-associated pathologies including cancer [75,86,93,143–154]. Experimental removal of accumulated p16
positive senescent cells in a progeroid mouse model was sufﬁcient
to reverse some age-associated pathologies, demonstrating that
accumulation of senescent cells is responsible for some tissue dysfunctions [155]. In the context of tissue repair, current evidence
suggests that senescent cells are normally eliminated in a process that involves immune system functions [156–161]. Whether
to stimulate tissue repair or their own elimination, senescent
cells actively interact with their tissue microenvironment, possibly
through direct cell–cell contacts, and undoubtedly using paracrine
signals (secretion). Protein secretion by senescent cells has been
collectively termed the Senescence-Associated Secretory Phenotype (SASP) [162]. Current data support the idea that senescent
cells interact with and modify their microenvironment using this
secretory program. Signaling elements regulating the SASP include
the DNA damage response (DDR), p38MAPK, the JAK/STAT pathway
and transcription factors such as NF-B and C/EBP␤ [163–168].
The SASP was originally documented indirectly through the
ability of senescent cells to inﬂuence the biology of other
cells [169]. Subsequently, mRNA proﬁling, targeted proteomics
(antibody arrays), and genome-wide RNA interference screens
have been used to characterize SASP factors and their effects
[163,164,170–174]. Multiple SASP factors have been directly validated for their ability to modulate the biology of senescent cells
or that of surrounding cells [175–177]. While individual SASP
components may vary depending on cell type and context, a few
ubiquitous SASP factors have emerged, including pro-inﬂammatory
IL6 and IL8, extracellular matrix remodeling MMP3, and growth
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promoting GroA [170]. The SASP supports positive aspects of
cellular senescence such as growth arrest and proper tissue
repair (Fig. 2). Autocrine activities include reinforcement of p53dependent growth arrest via cytokine signaling loops [163,164].
Paracrine activities include orchestrating the activity of specialized repair cells, including activated stellate cells, ﬁbroblasts and
immune cells, which are responsible for the resolution of wound
responses [156,157,159]. The SASP is also believed to modulate the
clearance of senescent cells by the immune system [157,159].
In some contexts, however, presumably when senescent cells
cannot be properly cleared by the immune system, negative consequences can occur [153,178–180]. Senescent cells may gradually
accumulate and displace normal cells, rendering affected tissues
dysfunctional. Senescent cells may also modify the local microenvironment making it more supportive of survival and/or growth of
potential pre-neoplastic cells. Following cancer therapy, surviving
cells exhibiting the SASP could create a protective microenvironment, or a niche, for subsets of cancer cells that can initiate
cancer recurrence. Cancer promoting effects of speciﬁc SASP factors have been shown in vitro and in vivo. For example, MMP3
secretion by senescent cells perturbed the proliferation and differentiation of cultured normal breast epithelial cells [181] while
secretion of HGF, AREG, or GroA increased proliferation of cultured cancer cells [173,174,182]. Cytokines IL6 and IL8 promoted
invasiveness and epithelial to mesenchymal transition (EMT) of
established cancer cell lines [173]. In xenograft models, senescent cells accelerated the growth of weakly tumorigenic human
cell lines [169]. This was attributed to MMP3 [183], but may also
involve other MMPs secreted by senescent cells [160]. Secretion of
VEGF may be responsible for increased vascularization observed in
xenograft models incorporating senescent cells [184]. Additional
data support a role of the SASP in cancer recurrence. For example, IL6 secretion by senescent cells in post-chemotherapy murine
thymus was sufﬁcient to create a protective niche for subsets
of lymphoma cells [167,185]. Similarly, SASP factors were linked
to recurrence of chemotherapy treated murine mammary cancers [186]. Finally, in another murine cancer model, secretion of
SASP factor WNT16B by senescent stromal cells supported continued growth of prostatic epithelial cancer cells after chemotherapy
[187]. Importantly, increased WNT16B levels were also detected in
post-therapy human prostate, ovarian, and breast cancers.

6. Determinants of senescence stability
Contrary to popular belief, the senescence growth arrest is
not always irreversible. Since senescence is a response to stress,
genomic and epigenomic aberrations that ameliorate stress (e.g.,
telomerase activation) or compromise cellular ability to sense or
transduce stress-related signals (e.g., p53 inactivation) have the
potential to promote immortalization and resistance to therapeutically induced senescence. Evidence obtained using cell sorting
and videomicroscopy showed that fully senescent non-malignant
human keratinocytes are capable of spontaneously yielding mitotically competent progeny [188]. Similarly, ﬂuorogenic tracer and
video microscopy were used to show that morphologically senescent cells in cultures of human mammary epithelial cells expressing
the NeuT oncogene are capable of dividing [189]. In addition,
fully senescent human ﬁbroblasts and human mammary epithelial
cells could be stimulated to resume proliferation by inactivating
p53 – provided the cells had not expressed p16 [122]. Human
mammary epithelial cells lacking the ability to express functional
p16 are prone to unstable growth arrest and chromosomal rearrangements during telomere dysfunction-induced senescence [48].
The genomic instability generated by telomere dysfunction can
complement pre-existing genetic aberrations to yield immortal
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Fig. 2. The senescence associated secretory phenotype (SASP) aids in the clearance of senescent cells, but can potentially promote proliferation of tumor cells that are not
stably growth arrested. Cell-autonomous growth arrest associated with senescence prevents the proliferation of damaged cells and is at least partially dependent on p53/pRB
pathways. In normal tissues, senescence also results in the activation of non-autonomous secretory factors that participate in wound response signaling, culminating in
senescent cell clearance and tissue repair (left panel). In cancer tissues (right panel), activation of non-autonomous secretory factors can be altered and/or increased by
treatment with therapeutic agents. However, cancer cells often harbor compromised p53/pRB pathways, and as a result, growth arrest may not occur or may be less stable.
Alterations in the types or abundance of secretory factors released by such cells may interfere with immune clearance and/or stimulate the growth of nearby cancer cells
that have escaped cell death. Important questions regarding the impact of senescence in the context of cancer therapy are highlighted in red.

cells [190,191]. Cells that emerge from such cultures display gross
genetic aberrations, many of which are also seen in human cancers
[54], suggesting that the same molecular lesions that enable escape
or circumvention of senescence in vitro occur during oncogenesis
in vivo.
Determinants of the stability of the senescence response have
not been well characterized. Yet, the implications of delayed cell
cycle re-entry or permanent senescence for patient prognoses are
profound. In the former case, transient senescence may allow tumor
cells time to repair or accommodate the chemotherapeutic stress
(e.g., damaged DNA), effectively conferring drug resistance [192].
Conversely, therapeutic efﬁcacy would be enhanced by enforcement of stable senescence in cancer cells that manage to retain
viability in the face of a therapeutic challenge. The mechanisms
determining these exclusive outcomes are poorly understood,
although clinical and experimental data indicate that the status of
p21 and p16, and associated tumor suppressors (e.g., p53, pRB) play
critical roles.
The reversibility of p16-induced growth arrest has been examined in human U2OS cells in which the transcription of an
exogenously introduced p16 gene was regulated by tetracycline
[193]. Induction of p16 for one day arrested most cells in the G1
phase of the cell cycle; if the inducer was then removed, p16 levels
returned to baseline and growth resumed within 3–5 days. If, however, p16 was induced for 6 days, DNA synthesis remained strongly
inhibited and the cells acquired morphological features of senescence. These results demonstrated that sustained p16 expression is
sufﬁcient to impose a stable block to cell proliferation that becomes
independent of p16 expression after a deﬁned period of time.
In another model employing breast cancer cell lines stably
expressing shRNAs against each of the individual RB family proteins, p16 induction still resulted in irreversible G1 growth arrest
in each case [194]. This ﬁnding suggests that there is some redundancy in the ability of the individual RB family proteins to mediate
irreversible growth arrest. Cases of functional redundancy within
this gene family have been reported in a number of murine and
human cell types [195,196]. This ﬁnding may explain why aberrations in upstream regulators such as p16, cyclin D1 and CDK4,
which presumably affect the regulation of all three RB family proteins simultaneously, are more common than aberrations in the
individual RB family proteins themselves in some cancers. From a

clinical standpoint, it is encouraging that even aggressive cancer
cells lacking both p53 and pRB tumor suppressors, are susceptible
to induction of irreversible senescence. This suggests that therapies
employing small-molecule inhibitors of CDK4/6 may be effective
even in some tumors lacking functional pRB.
A representative small molecule CDK inhibitor that has recently
been approved for clinical use is PD0332991 (Palbociclib; Supplementary Table 1). This drug has been tested against 39 individual
serine, threonine, and tyrosine kinases, representing most of the
primary protein kinase families, and has shown highly selective inhibition of CDK4 and CDK6 [197–199]. Importantly, oral
PD0332991 administration alone at doses that were well tolerated by host animals was sufﬁcient to cause regression of a variety
of human tumor xenografts [197]. The mechanism by which this
small molecule causes tumor regression in xenograft studies has
been unclear, since in short-term cell culture studies (72 h) it has
been shown to cause cytostasis rather than cytotoxicity [197].
Recent assessment of PD0332991 using short-term growth assays
indicated that it was effective in inducing growth arrest of many
estrogen receptor (ER) positive breast cancer cell lines, but that a
number of ER(−) lines were able to maintain pRB phosphorylation
and proliferation in its presence [200]. Several of the ER(−) cell lines
exhibiting resistance to the CDK4/6 inhibitor retained phosphorylated pRB in the presence of the CDK4/6 inhibitor. This indicates
that another kinase, most likely CDK1 or CDK2, was capable of
phosphorylating and inactivating pRB in the absence of CDK4/6
activity in these cell lines. Thus, in many ER(−) breast cancer cells,
targeting of CDK1 or CDK2 instead of, or in addition to, CDK4
may be required to initiate senescence. However, if the resulting
senescence response is not stable, this may be clinically counterproductive. Indeed this danger was illustrated in a recent report
that showed CDK4/6 inhibition protected ER(−) breast cancer cells
from doxorubicin-mediated cytotoxicity [201].
Supplementary table related to this article can be found, in the
online version, at doi:10.1016/j.semcancer.2015.03.007.

7. Defects in telomerase regulation
Telomerase is almost universally re-expressed in cancer cells
and is regulated at multiple levels involving genetic, epigenetic,
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transcriptional, post-transcriptional, post-translational, and subcellular shuttling mechanisms. At the genetic level, both hTR and
hTERT genes have been reported to be ampliﬁed in some tumors.
Increased hTR gene copy number was detected frequently in head
and neck and cervical carcinomas [202] while hTERT gene ampliﬁcations have been found in primary cancers and cell lines, including
those of brain, breast, cervix, liver, and lung [203–205], as well
as primary and metastatic melanomas [206]. In most cases, the
ampliﬁed region encompassed most or all of chromosome 5p
[13,203,206]. However in several cases, chromosomal break points
were mapped to regions close to the hTERT promoter, suggesting that chromosomal rearrangements could either relieve the
promoter from its stringent repressive epigenetic environment or
place it in the proximity of enhancers at different chromosomal
sites [207]. Genetic polymorphisms may also contribute to variations in telomere length and cancer development. In a recent
genome wide association study, single nucleotide polymorphisms
(SNPs) in seven loci were found to be associated with differences in
mean leukocyte telomere length and risks of cancer and other agerelated diseases [208]. These loci corresponded to genes encoding
hTERT and hTR, as well as other proteins involved in telomerase
complex assembly and telomere maintenance. SNPs in multiple
regions of the hTERT locus, including the promoter and downstream introns, were shown to be associated with telomere length
and risks of various malignancies, including breast, ovarian, and
prostate, glioma, lung, and urinary bladder cancer [209–211].
Both the hTR and hTERT genes are subject to tumor speciﬁc
epigenetic regulation. H3-K9Me marks were increased at the hTR
promoter in normal ﬁbroblasts and in several ALT cell lines with
low hTR expression in comparison with telomerase positive cancer cell lines, suggesting a role in hTR suppression, while H3-K4Ac,
H4-K4Ac, H3-K9Ac and H3-K4Me were associated with hTR expression. Similar analysis of the hTERT promoter also revealed H3-K9Me
associated with transcriptional suppression and higher levels of
H3-K4Ac, H4-K4Ac and H3-K9Ac in cancer cells compared with normal ﬁbroblasts, though H3-K4Me was not strongly associated with
expression in the panel tested [212].
In cancer cells lacking chromatin mediated silencing present
in normal cells, both genes are subject to regulation by a wide
variety of distinct, but overlapping, transcription factors. hTR is
generally expressed at low levels in normal cells and is substantially up-regulated in cancer cells as shown both by ﬂuorescence
in situ studies of a wide range of tumor samples [213] and by tumor
speciﬁc expression of hTR promoter-driven transgenes in the setting of gene therapy studies [214,215]. The hTR gene promoter is
activated by NF-Y, Sp1, pRB and HIF1, and is suppressed by Sp3,
MDM2 and active JNK signaling which causes a switch from Sp1
to Sp3 binding at the endogenous promoter [216–218]. However,
beyond these ﬁndings, relatively little attention has been paid in
the literature to hTR transcriptional mechanisms.
In contrast, the hTERT gene has been intensely studied since its
molecular cloning in 1997 (Fig. 3). hTERT transcripts are nearly or
completely undetectable in most normal cells, but are expressed
at low levels which are sufﬁcient to drive telomere maintenance
in cancer cells. Substantial work has focused on the core promoter
region, which is sufﬁcient for tumor speciﬁc activity. This region
contains a number of binding sites for known transcription factors
including c-Myc, HIF1, ETS, E2F and Sp1/Sp3, which integrate hTERT
transcriptional responses with a number of important pathways
that are dysregulated in various tumor types [219–221]. Interestingly, HIF1 is also involved in post-transcriptional regulation of
hTERT splicing [222].
In general, oncogenic growth promoting pathways have usually
been found to activate telomerase expression and promoter activity, while pathways controlling growth suppression, cell death and
senescence have the opposite effect. For example, growth factor
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signaling through MAPK pathways increases hTERT expression in
part via ETS factors [223]. Interestingly, recent studies have shown
that telomerase can be activated by point mutations in the hTERT
core promoter occurring with particularly high frequency in both
familial and sporadic melanoma samples [224,225]. These mutations occurred more frequently than BRAF or NRAS mutations and
each generated a binding site for ETS family transcription factors, including the TCF subgroup activated by MAPK and BRAF
signaling.
Other hTERT activation pathways that are frequently deregulated in various cancer settings include those inﬂuenced by CDK2
and CDK4 [226] and AKT [227], whereas deregulated repression
pathways include those inﬂuenced by TGF␤ [228], TNF␣ [229], and
other cell cycle inhibitors [230]. Disrupted developmental pathways can cause hTERT expression. For example, the hTERT gene has
been found to be a direct target of the Wnt signaling [231–233].
The Wnt signaling pathway is known to play essential roles in
development and stem cell renewal. Binding of Wnt ligand to its
receptor Frizzled activates GSK3␤ kinase, which blocks ubiquitindependent degradation of ␤-catenin. Stabilized ␤-catenin enters
the nucleus, forms a complex with LEF/TCF, and activates a set
of target genes including c-Myc. Myc protein binds to an E-box
element in the hTERT core promoter and activates hTERT transcription. In addition, ␤-catenin can also form a complex with
transcription factor Klf4 and bind to the hTERT promoter directly
[231].
Recently, a whole kinome siRNA screen in ovarian cancer cells
for regulators of the hTERT promoter revealed at least 68 kinases
that participate in pathways upstream of hTERT regulatory transcription factors, underscoring the complexity of the signaling
environment [234]. Hence, it is perhaps more useful and realistic to consider hTERT regulation in a systems context as a dynamic
network, in which cell-speciﬁc mechanisms are likely to come into
play, than to focus on individual factors. For example, while c-Myc
has been shown to activate hTERT transcription in cancer cells and
some normal cells [235], moderate overexpression of c-Myc by
itself is not sufﬁcient for activation of endogenous hTERT genes in
normal human mammary epithelial cells [191]; in the latter case,
additional genomic alterations were needed for telomerase activation and cellular immortalization. Many other factors bind the
extended hTERT promoter region, co-operating with those at the
core promoter and with upstream pathways. Different combinations of transcription factors may activate telomerase expression
in speciﬁc cancer cells. Given this complexity, there is clearly a
need for approaches to study telomerase regulation at the systems
level. A possible positive implication of the complexity is that, if
sufﬁciently well understood, it could lead to precise therapeutic
ablation of telomerase expression in cancer cells through combinatorial targeting of cooperating factors in speciﬁc cancer cell
contexts.

8. Therapeutic targeting of telomerase
Intrinsic differences in telomere maintenance between normal
and cancer cells provide an attractive therapeutic opportunity. Several direct strategies to exploit the dependence of cancer cells
on aberrant telomerase expression for telomere homeostasis and
immortality have been reported. The key advantages of targeting telomerase in comparison with most other cancer targets are
its relative universality, criticality and speciﬁcity for cancer cells,
including putative cancer stem cells [236]. Approximately 90%
of human cancers and virtually all adenocarcinomas display signiﬁcantly higher levels of telomerase compared to normal cells,
thereby implicating telomerase as an intriguing target of potential
anticancer therapeutics [22]. No other tumor-associated marker
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Fig. 3. Mediators of hTERT activation and repression. Green arrows (top panel) indicate reported interactions that activate, while red arrows (bottom panel) indicate reported
interactions that inhibit hTERT. Letters indicate mechanism (TR, transcriptional regulation; B, binding; -/+P, de/phosphorylation; IE, inﬂuence on expression).

is as widely expressed. Moreover, telomerase, encoded by nonredundant genes, is the most efﬁcient known mechanism for
maintenance of telomeres and replicative immortality. Although
a telomerase-independent alternative lengthening of telomeres
(ALT) mechanism exists for telomere maintenance in cell lines
and cancers in which telomerase is not active or is suppressed
[237,238], some studies suggest that ALT cells are not as biologically robust as telomerase-positive cancer cells, and may have

heightened susceptibility to drug regimens that induce oxidative stress [239,240]. Thus cancers may be less likely to develop
resistance to telomerase-based therapies than to other targeted
therapies whose targets may be compensated for by functionally
similar proteins and pathways. In addition, the low or transient
expression of telomerase in normal tissues, including normal stem
cells, and the generally longer telomeres in normal stem cells versus
cancer cells, provide degrees of speciﬁcity to telomerase-based
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drugs and reduce the probability of toxicity to normal tissues [241].
All of these factors suggest that cancer drugs based on telomerase
might have a high therapeutic index.
Many distinct classes of anticancer compounds directed toward
telomerase can conceivably be developed because of the varied
cellular processes that regulate telomerase expression and activity. For example, cellular telomerase activity can be controlled
through changes in gene transcription and alternative splicing
of the telomerase components, and by the nuclear translocation,
phosphorylation, folding and turnover of individual components
that lead to and regulate the rate of telomerase complex assembly
and accessibility to telomeres [242,243]. The therapeutic potential of targeting telomerase-mediated telomere maintenance in
cancer cells was ﬁrst demonstrated by expression of a dominant
negative mutant form of hTERT (DN-hTERT) in tumor-derived cell
lines [31,244]. These studies showed that inhibition of telomerase
in solid tumor and leukemia cell lines induced progressive telomere shortening and eventual proliferative arrest or cell death
via apoptosis. They also demonstrated that expression of DNhTERT inhibited anchorage independent growth and impeded the
development of malignancies in xenografted mice [245–248]. The
inhibitory effects of DN-hTERT were also experimentally demonstrated using primary AML cells in vitro and in vivo using a murine
model [248].
8.1. Oligonucleotide inhibitors
Studies that utilized antisense oligonucleotides, including
chemically modiﬁed nucleic acids (PNA) that target hTR, provided proof-of-principle evidence of the effectiveness of this
approach as a means of speciﬁcally inhibiting telomerase and
inducing telomere shortening [249–254]. In human tumor cell
lines, 2 -O-MeRNA, phosphoramidate and PNA oligomers induced
telomere shortening with the subsequent onset of apoptosis over
long-term culture periods [252,254–256]. In particular, a N3 –P5
thio-phosphoroamidate oligonucleotide targeted to the template
region of human hTR (GRN163) was shown to have efﬁcacy against
multiple myeloma and non-Hodgkin’s lymphoma cell lines, as well
as activity toward patient-derived cells [256–258]. The speciﬁcity
of this compound was evidenced by telomere shortening, and by
the relatively high sensitivity of multiple myeloma cells with short
telomeres in comparison to cells with longer telomeres [257,258].
A lipid conjugated form of GRN163, referred to as GRN163L or imetelstat, exhibited improved cell uptake and was shown to more
effectively inhibit telomerase, cause more rapid telomere shortening and thus elicit more rapid growth arrest than the non-lipidated
compound [259,260]. Although one study reported that imetelstat
caused cultured mesenchymal stem cells (MSCs) to arrest in G1
phase of the cell cycle, the MSCs were able to resume growth after
imetelstat was removed [261]. Therefore, short-term imetelstat
exposure did not appear to induce senescence or cell death in MSCs.
The efﬁcacy of imetelstat against cancer cells was demonstrated in
a variety of preclinical models, including mice xenografted with
human cell lines derived from liver, breast, lung and prostate cancers, as well as multiple myeloma [259,262–265]. Together, the
preclinical studies of imetelstat validated targeting the template
region of hTR as an effective approach to telomerase inhibition.
However, evidence also emerged from these studies suggesting
that in addition to inhibiting telomerase, imetelstat also has off
target effects that disrupt the cytoskeleton and alter adhesive properties of tumor cells [266,267]. Inhibition of breast and lung cancer
metastases in an animal model was attributed to this telomeraseindependent action of imetelstat [266].
Following the success of the preclinical investigations of imetelstat, phase 1 clinical trials were initiated in which imetelstat was
tested as a single agent in patients with various aggressive liquid
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and solid tumors (Supplementary Table 1). The limited information that was released following the completion of those studies
suggested that imetelstat presented minimal adverse effects, with
thrombocytopenia and neutropenia being the dose limiting toxicity [236] (http://www.geron.com/imetelstat). Subsequent phase II
trials have focused on hematologic disease, childhood CNS malignancies and the application of imetelstat in maintenance therapy
for non-small cell lung cancer and metastatic breast cancer patients
previously treated by standard chemotherapy and surgical debulking. Data emerging from these trials suggest limited beneﬁt in these
speciﬁc clinical settings. Disappointing progression-free survival
results from a phase 2 trial of imetelstat as maintenance therapy following platinum chemotherapy in patients with non-small cell lung
cancer have led the Geron Corp. to suspend further development of
imetelstat in solid tumors. However, it has been argued that results
from the lung cancer trial showed improved outcomes for a small
subset of patients with tumors that had short telomere lengths.
Among the trials for hematologic disorders, encouraging data from
13 patients treated with imetelstat for essential thrombocythemia
were presented at the annual meeting of the American Society for
Hematology in December 2012. The ability of imetelstat to reduce
platelet counts in essential thrombocythemia is consistent with
earlier trials that reported thrombocytopenia as an adverse effect.
While imetelstat, targeting hTR, was the ﬁrst telomerase
inhibitor to undergo trials in patients, modiﬁed antisense oligonucleotides targeting hTERT mRNA have also been shown to impede
the proliferation of tumor cells. However, in contrast to the lag
period observed in preclinical investigations of imetelstat, the
proliferative defect induced by hTERT inhibition was immediate,
and occurred in the absence of apparent telomere shortening
[268–270]. A modiﬁed oligonucleotide directed toward hTERT
mRNA was also shown to sensitize leukemic cell lines and primary
cultures established from AML and CML patients to the drug cisdiamminedichloroplatinum. Ribozymes and small interfering RNAs
(siRNAs) targeting hTERT have also been employed to suppress telomerase activity, impede proliferation, and sensitize tumor cells
to cytotoxic drugs [271–275]. The potent anti-proliferative effects
that have been demonstrated in tumor cells depleted of hTERT are
consistent with a body of evidence that describe telomere-length
independent functions of hTERT and gene expression changes
induced by repression of hTERT [276–281]. These observations further highlight the potential beneﬁt of direct therapeutic targeting
of hTERT, although the translation of these ﬁndings to the clinic
await the development of new technologies for efﬁcient delivery
of siRNA and ribozymes to tumor cells.
8.2. Small molecule telomerase inhibitors
Small molecular weight compounds that inhibit telomerase
activity have been identiﬁed in screens of chemical libraries
or synthesized based on the structure of the tea catechin,
epigallocatechin-3-gallate (EGCG; see Section 8.4), which is
a known naturally occurring telomerase inhibitor [282–287].
Small molecular weight telomerase inhibitors characterized
to date belong to a range of chemical classes and include
2-[3-(triﬂuoromethyl)phenyl]isothiazolin-3-one (TMPI), Rhodacyanine (FJ5002), N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]2,3-dihydroxybenzamide (MST-312) and (E)-2-(3-(naphthalene-2yl)but-2enamido)benzoic acid (BIBR1532). BIBR1532 is one of the
more extensively used inhibitors and was shown to induce telomere shortening, impede proliferation of tumor cell lines in vitro
and limit tumor formation in xenografted mice [284,288,289]. At
a low concentration (10 m), BIBR1532 had no effect on shortterm proliferation or survival, whereas higher concentrations
(50–80 m) were acutely cytotoxic. Notably, toxicity was also
observed when telomerase-negative leukemia cells were treated
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with a high concentration of the BIBR1532. The cytotoxic effects
of BIBR1532 were attributed to telomere uncapping, however nontelomeric effects have not been ruled out. Limited bioavailability
of this compound has prevented its translation to clinical trials in
patients.
Other indirect approaches to targeting telomerase can and are
being considered. A range of pathways and mechanisms may be
tractable for such inhibition. For example, the PI3K-Akt-mTOR
pathway regulates cell size, progression of the cell cycle, and cell
survival, and is considered a master regulator of protein synthesis
[290]. mTOR – a serine/threonine kinase – is frequently dysregulated in cancer cells [291]. An association between mTOR and
telomerase activity has been shown using the prototypical mTOR
inhibitor rapamycin that, in addition to its other effects, causes
inhibition of telomerase activity [292–296]. Some phytochemicals
(see below) act in a similar manner to rapamycin with respect to
telomerase inhibition [294,297].
8.3. Immunotherapeutic approaches
Studies that demonstrated telomerase antigens on the surface of tumor cells provided impetus for pursuing telomerase
immunotherapy as a therapeutic approach to the treatment of
the broad spectrum of human malignancies that express telomerase [298–300]. Following preclinical studies of telomerase
immunotherapy for treatment of leukemia and other malignancies [301,302], immunotherapy products were developed for use
in telomerase vaccination clinical trials [236,303] (Suppl. Table 1).
Indeed one product, GV1001, has progressed to phase III clinical trials, in which it is being used in combination with gemcitabine for
the treatment of pancreatic cancer [236]. Concerns that telomerase
immunotherapy may be detrimental to normal hematopoietic progenitor cells were somewhat allayed by investigations that showed
there was no signiﬁcant reduction in the frequency of clonogenic
progenitor cells or NOD/SCID repopulating cells within the bone
marrow of cancer patients after vaccination [304]. In accordance
with this result, limited hematologic toxicity, such as grade I anemia
and thrombocytopenia, were reported to occur during telomerase
vaccine trials [236].
8.4. Telomerase-directed gene therapy
The general aim of most tumor speciﬁc gene therapy is to
selectively kill cancer cells while leaving normal cells unharmed
by expressing high concentrations of a therapeutic protein only in
malignant cells. Transcriptional targeting, in which a therapeutic
gene is placed under transcriptional control of a tumor-speciﬁc promoter, is a potentially powerful tool to achieve this aim. Although
their activities are quite different, the promoters for hTERT and hTR
are attractive candidates for use in gene therapy since they are both
active in the vast majority of cancer cells tested [17]. Most telomerase gene therapy strategies that have been tested can be broadly
categorized as cytotoxic gene therapy or oncolytic virotherapy
approaches, both of which aim directly to kill cells expressing telomerase while sparing normal cells that do not, thereby
circumventing the issue of the phenotypic lag in cells in which telomerase activity is merely blocked [17]. Using these gene therapy
approaches, cell lines covering most of the major common malignancies have been targeted effectively in vitro. Critically, almost all
of these studies have shown speciﬁcity using normal cell strains.
Efﬁcacy against xenograft models has also been repeatedly shown
across multiple tumor cell types. Although there is a concern that
the activities of the core telomerase promoters in normal mouse tissues may not reﬂect their activities in human, several groups have
shown that systemic delivery of telomerase-speciﬁc gene therapy
constructs does not result in signiﬁcant off-target liver toxicity.

In addition, the biodistribution of systemically delivered hTR and
hTERT-speciﬁc transgene expression has been investigated by
imaging and reporter assays; activity appears to be low or absent
in normal tissues (for a review of efﬁcacy and selectivity data, the
reader is referred to tables in [17]). Therefore, proof-of-principle
broad spectrum, selective targeting by the telomerase promoters
has been convincingly shown in preclinical models.
8.5. Phytochemicals
Attractive anticancer agents due to their low cost and accessibility in diets, phytochemicals may have selective telomeraseinhibiting and senescence-inducing properties. Experimental
evidence obtained in cultured human cancer cells suggests that
a variety of natural phytochemicals from dietary and non-dietary
sources represent promising sources of chemotherapeutic agents
that can potentially target telomerase with few side effects
(reviewed in [242,297,305]). Regulation of telomerase activity
and/or expression, localization of speciﬁc components of the
telomerase protein–RNA complex or posttranslational modiﬁcations by phytochemicals have been observed. Among the ﬁrst
phytochemicals reported to repress telomerase was the compound berberine, leading to identiﬁcation of the more potent
anti-telomerase analogue FJ5002 [282], though this was not further developed. Indicative of the complexities of understanding
the precise mechanism of action of natural products, tested phytochemicals appear to disrupt different telomerase-associated
processes in cancer cells from different tissue sources [242]. Also, a
few studies have shown that certain phytochemicals can inhibit
or stimulate expression of telomerase components in different
cancer cells [242]. Because of the varied effects on telomerase, speciﬁc sets of phytochemicals could conceivably be used alone or
as complementary agents in combinational therapeutic strategies
with established protocols for the prevention and/or treatment of
human cancers. Examples of phytochemicals with demonstrated
bioactivity against telomerase include (a) isoprenoids – such as
perillyl alcohol, genistein, and ﬁsetin, (b) polyphenols – such as
curcumin, resveratrol, and EGCG, (c) indole-3-carbinol, and (d) sulforaphane (Table 1).
Among the isoprenoids, perillyl alcohol, a small, lipophilic product of the plant mevalonate biosynthetic pathway [306–308],
suppresses the growth of tumor cells in culture as well as in
rodent models [309–313]. Perillyl alcohol acts on protein translation through modulation of mTOR signaling in cultured prostate
cancer cells [314] and in mice with intracranial gliomas [310].
Mechanistically, perillyl alcohol has been shown to disrupt complex formation between mTOR and hTERT, causing p70 S6 kinase
(S6K), heat shock protein 90 (Hsp90), and hTERT to dissociate from
the regulatory-associated protein of mTOR (RAPTOR) [293,294].
Genistein – another isoprenoid found in soy and fava beans –
has independently been shown to down-regulate telomerase activity and attenuate 4E-BP1 phosphorylation, an indicator of mTOR
signaling [314–316]. Genistein down-regulates hTERT levels by
the inhibiting hTERT gene promoter activity in human prostate
cancer cells [315]. This study also showed that exposure to genistein inhibited expression of the c-Myc, possibly attenuating its
transcriptional activation of the hTERT promoter; however, the
inhibitory effects of genistein on hTERT promoter activity likely
require the disruption of one or more factors in addition to cMyc. One contrasting study showed that genistein stimulated
hTERT expression in reproductive cancer cells by enhancing STAT3
activity [317], however, the biological context of this observation is not well understood. Consistent with the transcriptional
inhibitory effects of genistein, treatment of lung cancer cells with
the ethyl acetate fraction of ginger extracts concurrently down regulated hTERT and c-Myc expression, which resulted in a loss of
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Table 1
Therapeutic targeting by select phytochemicals.
Phytochemical

Targets

Current state of evidence

Perillyl alcohol

mTOR [292–296,310,314]
Telomerase [292–296]
Ras-Erk [309,310]
mTOR [326,327,373,374]
Telomerase [322–325,375]
Akt [326,373]
Hsp90 [325]
NF-B [328,375]
JAK/STAT [328,376]
MAPK [328,329]
mTOR [334,381]
Telomerase [332,333]
Akt [334,382]
MAPK [383,384]
mTOR [335,388]
Telomerase[336–339]
PI3K[335,388]
NF-B [335,389]
JAK/STAT [335,390]
MAPK [335,391]
mTOR [314,398]
Telomerase [315,316]
Akt [314]
mTOR [319,320]
PI3K/Akt [319,320]

Cell lines [292–296,310,311,314,368]
Animal models [307–311]
Clinical trials [369–372]
Cell lines [322–327,373,375,376]
Animal models [334,373–375]
Clinical trials [377–380]

Curcumin

Resveratrol

EGCG

Genistein

Fisetin

telomerase activity [318]. Genistein also has a strong posttranslational effect on telomerase compartmentalization in prostate
cancer cells where it caused down-regulation of the Akt dependent phosphorylation of hTERT and thereby inhibited hTERT
translocation into the nucleus [315]. Another structurally similar
phytochemical, ﬁsetin, decreases phosphorylation of multiple proteins within the Akt and mTOR pathway, including PI3K, mTOR, S6K
and 4E-BP1 [319,320]. Furthermore, ﬁsetin has shown antitumor
efﬁcacy in Lewis mouse lung tumor models [321].
Among polyphenolic compounds, curcumin – a component
of the spice turmeric, has also been shown to inhibit telomerase directly and indirectly in human brain, breast, cervical, and
leukemic cell lines [322–325]. This phytochemical reduces mTOR
signaling by inhibiting phosphorylation of S6K and 4E-BP1, and
disrupts the mTOR–RAPTOR interaction [326–328]. Like other phytochemicals, curcumin has a range of pleiotropic effects and has
been reported to modulate the expression and/or activity of a range
of pro- and anti-apoptotic proteins as well as telomerase regulatory
factors such as c-Myc and the p53 family [324]. In addition to its
effects on mTOR, curcumin modulates additional cellular pathways,
including JAK-STAT, NF-B, and MAPK, that impact telomerase regulation and cancer cell growth [328,329]. In breast cancer cells,
curcumin down-regulation of the levels of the NFkB transcription
factor has been proposed to attenuate hTERT expression [330]. In
lung cancer cells, curcumin stimulates the level of reactive oxygen
species, which triggers the proteasome degradation of the Sp1 transcription factor leading to the loss of hTERT gene expression [331].
Curcumin exposure was also shown to stimulate the cytoplasmic
retention of hTERT protein by causing dissociation of hTERT from
its chaperone p23 [325]. Resveratrol, another natural phenol produced in many plants including grapes, has been found to decrease
hTERT protein levels and inhibit telomerase activity [332,333]. The
combination of curcumin and resveratrol reduced cancer incidence
in PTEN knockout mice [334]. EGCG is similar to curcumin in that
it was found to modulate multiple oncogenic signaling pathways
such as JAK/STAT, MAPK, and PI3K/Akt/mTOR [335]. EGCG downregulated telomerase activity in multiple carcinoma cell lines and
in mouse xenograft tumors [336–339].
Other phytochemicals with demonstrated telomerase regulatory properties include indole-3-carbinol, a naturally occurring

Cell lines [332,333]
Animal models [334,381,384]
Clinical trials [385–387]
Cell lines [336–339,389,390,392,393]
Animal models [337,338,394]
Clinical trials [395–397]

Cell lines [314–316]
Clinical trials [399]
Cell lines [319,320]
Animal models [321]

hydrolysis product of glucobrassicin, and the dietary isothiocyanate, sulforaphane, both from cruciferous vegetables such as
broccoli and Brussels sprouts. Treatment of cultured breast cancer
cells with indole-3-carbinol induced cell cycle arrest and disrupted
combined estrogen receptor-alpha and Sp1-driven transcription of
the hTERT gene [340]. Chromatin immunoprecipitation analysis of
the endogenous hTERT promoter showed that indole-3-carbinol
inhibited binding of both estrogen receptor-alpha and Sp1 to a
composite estrogen response-Sp1 element in the hTERT promoter
[340]. Similar to curcumin, exposure to sulforaphane elevated
intracellular reactive oxygen species in hepatocellular carcinoma
cells and this process was functionally linked to the inhibition of
hTERT gene expression [341]. In hepatocellular carcinoma cells and
in breast cancer cells, sulforaphane suppressed Akt kinase activity,
which resulted in the loss of hTERT phosphorylation [341].
Candidate telomerase inhibitory natural products are not
restricted to phytochemicals. Axinelloside A, a sulphated
lipopolysaccharide isolated from the marine sponge Axinella
infundibula, is found to inhibit telomerase [342]. However, no
further studies in relation to telomerase have been reported
using this highly complex compound. Telomestatin is a natural
macrocyclic pentaoxazole isolated from Streptomyces anulatus that
inhibits telomerase activity and causes telomere shortening and
apoptosis in a range of cancer cell lines in vitro as well as leukemia
xenografts. Telomestatin also augments apoptosis induced by various chemotherapeutic agents [343–346]. However, its puriﬁcation
is inefﬁcient and total synthesis is highly complex [347,348].
9. Therapeutic targeting of telomeres
Another plausible approach to the inhibition of telomere maintenance is to directly target telomeres, or to manipulate the
shelterin proteins that provide telomere secondary structure and
telomerase access (reviewed in [3]). One potential target that has
attracted considerable interest is tankyrase 1, a poly(ADP-ribose)
polymerase (PARP) family protein that modiﬁes the shelterin
protein TRF1 [349,350]. By modifying TRF1, tankyrase 1 causes
displacement of TRF1 from the telomere, thereby promoting telomere unfolding and enabling telomerase to access and lengthen
the telomere. General PARP inhibitors have been shown to impede
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Table 2
Cross-validation of selected targets and agents.
Targets for replicative
immortality
Other cancer hallmarksa
Genomic instability
Sustained proliferative
signaling
Tumor promoting
inﬂammation
Evasion of anti-growth
signaling
Resistance to apoptosis
Dysregulated
metabolism
Immune system
evasion
Angiogenesis
Tissue invasion and
metastasis
Tumor
microenvironment
Approaches

Other cancer hallmarksb
Genomic instability
Sustained proliferative
signaling
Tumor promoting
inﬂammation
Evasion of anti-growth
signaling
Resistance to apoptosis
Dysregulated
metabolism
Immune system
evasion
Angiogenesis
Tissue invasion and
metastasis
Tumor
microenvironment

Telomerase
(inhibit)

hTERT (inhibit)

mTOR (inhibit)

CDK4/6
(inhibit)

CDK1/2/5/9
(inhibit)

Akt (inhibit)

PI3K (inhibit)

+/−
[400–402]c
+
[410]
+
[410]
+
[258,276,435]
+
[447]
+
[453]
0

+/−
[400–402]
+
[411–413]
+
[410]
+
[258,276,435]
+
[448]
0

0

−
[403]
+
[417,418]
+
[428]
+
[438,439]
+
[450]
+
[455]
0

+
[404,405]
+
[419–421]
+
[429,430]
+
[440–442]
+
[451]
+
[456]
0

+
[465]
+
[472,473]
+
[481]

+
[465]
+
[472,473]
+
[482]

+
[468,469]
+/−
[476,477]
+
[484]

+
[470,471]
+
[478,479]
−
[485,486]

+
[406–408]
+
[415,422,423]
+
[431,432]
+
[443,444]
+
[452]
+
[457,458]
+
[462]
+
[466]
+
[480]
+
[487,488]

+
[409]
+
[424,425]
+
[433,434]
+
[445,446]
+
[452]
+
[459,460]
+/−
[463,464]
+
[466]
+
[475]
+
[488,489]

0

+
[414–416]
+
[426,427]
+/−
[436,437]
+
[449]
+
[454]
+/−
[461]
+
[466,467]
+
[474,475]
+
[483]

GRN163L
(imetelstat)

Genistein

Perillyl
alcohol

PD 0332991
(palbociclib)

SCH 727965
(dinacicilib)

Curcumin

EGCG
(epigallocatechin3-gallate)

+/−
[490,491]
0

+/−
[492,493]
+/−
[499,500]
+/−
[508–510]
+
[517–519]
+
[527,528]
+
[537]
+
[541]
+
[547–549]
+/−
[554–556]
+
[563]

+
[494]
+
[501,309]
+
[309,511]
+
[520]
+
[529,530]
+
[310]
0

0

0

+
[502]
0

+
[503]
0

+
[502,521]
+
[502,531]
0

+
[522]
+
[522,532]
0

0

0

+
[550]
+
[310]
+
[550]

0

0

−
[476]
0

+
[503]
+
[564]

+
[495,496]
+
[504,505]
+
[512–514]
+
[523,524]
+
[533,534]
+
[538]
+
[542,543]
+
[551]
+
[557,558]
+
[565,566]

+/−
[497,498]
+
[506,507]
+
[515,516]
+
[525,526]
+
[535,536]
+
[539,540]
+/−
[544–546]
+
[552,553]
+
[559–561]
+
[567]

0
+
[258]
+
[276]
0
0
0
0
+
[562]

a
Potential consequences of targeting indicated protein complexes involved in the maintenance of replicative immortality on other hallmarks of cancer: +, inhibition of
indicated target has beneﬁcial consequences for hallmark; −, inhibition of indicated target exacerbates hallmark; +/−, inhibition of indicated target has both positive and
negative effects on hallmark; 0, no published evidence of any effect on hallmark.
b
Potential consequences of the use of selected agents targeting pathways involved in the maintenance of replicative immortality on other hallmarks of cancer: +, indicated
agent has beneﬁcial consequences for hallmark; −, indicated agent exacerbates hallmark; +/−, indicated agent has both positive and negative effects on hallmark; 0, no
published evidence of any effect of indicated agent on hallmark.
c
Numbers in brackets refer to references containing evidence for potential consequences listed.

telomere length maintenance and augment the activity of the
telomerase inhibitor MTS-312 in experimental systems [349]. Compounds that speciﬁcally inhibit the PARP activity of tankyrase 1 are
now available for experimental purposes and provide a starting
point for the development of tankyrase inhibitors for advancement
to clinical trials [351]. Since tankyrase 1 is known to modulate the
activity of pathways that that contribute to cancer cell proliferation
independently of telomerase (e.g., the WNT/␤-catenin pathway),
this area of investigation holds considerable promise.
There is a body of evidence that suggests that the 3 G-rich
single stranded overhang of the telomere forms a G-quadruplex
structure that is not accessible to telomerase [352,353]. Gquadruplex stabilizers therefore present a possible alternate means
of manipulating telomere maintenance in cancer cells. Molecules
that stabilize G-quadruplexes and have been tested for telomere effects include porphyrins (TMPyP4), perylenes (PIPER),

acridine derivatives (BRACO19, RHPS4), quinoline-substituted triazines and natural products, such as telomestatin [354–358]. At
non-toxic concentrations, these compounds diminished telomerase enzyme activity, induced telomere shortening and arrested
tumor cell proliferation after a lag period [358,359]. Decreased
tumor growth rates were also demonstrated in mice xenografted
with leukemia cells [343,344,360]. G-quadruplex stabilizing agents
may also facilitate the action of standard chemotherapeutic agents and molecular targeted treatments [356,359]. For
instance, telomestatin was shown to enhance the sensitivity of
acute myeloid leukemia cells to danunorubicin and cytosinearabinoside, and was effectively combined with the tyrosine kinase
inhibitor imatinib to kill chronic myeloid leukemia progenitor
cells [247,344,361]. These results clearly illustrate the potential
of G-quadruplex stabilizing agents for the treatment of malignancy.
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10. Other potential therapeutic targets
Because of a lack of deﬁnitive molecular criteria, there is
currently no consensus regarding properties that contribute to efﬁcient senescence induction. Conceivably, any compound or agent
that causes DNA damage or otherwise alters replication may cause
senescence at doses that are not cytotoxic. Additionally, agents that
stimulate differentiation pathways (such as retinoic acid [362]),
may induce senescence in cancer cells that are not able to respond
appropriately; this phenomenon which so far has received little
attention, can potentially be the basis of truly non-toxic alternative therapies. The therapeutic utility of speciﬁc compounds will
depend on standard factors such as whether activation is required,
uptake and retention, as well as detoxiﬁcation and repair capacities of the target cells versus those of normal cells providing
vital functions. Beyond these considerations, however, the speciﬁc
genetic and epigenetic traits of prospective target cells are likely
to have large inﬂuences on senescence susceptibility and stability.
For example, while conventional genotoxic chemotherapy is often
effective at inducing senescence when used at maximally tolerated
doses, tumor resistance and recurrences remain signiﬁcant clinical problems, particularly in patients whose tumors retain intact
p53 responses [363,364]. When treated with genotoxins, wild-type
p53 tumors show induction of p21 and SA-␤gal, but not p16, and
tumor growth often recurs after treatment [364]. Tumor recurrence
might be signiﬁcantly impeded in these cases through the concurrent administration of CDK inhibitors that circumvent defects in
the p16/pRB pathway, causing the activation of RB-family dependent heterochromatin formation at E2F-dependent promoters, and
stabilization of the senescent phenotype in target cells. Similarly,
telomere and telomerase targeting therapies might be improved by
the inclusion of agents that induce oxidative stress to discourage
the selective outgrowth of ALT+ cells [240].
11. Opportunities for senescence drug discovery
In terms of drug discovery, components of the various senescence pathways represent potential targets. To determine whether
or not accelerated senescence is a desirable clinical outcome of cancer therapy, it will be necessary to develop efﬁcient and speciﬁc
approaches to modulate relevant pathways in order to activate the
response in a predictable fashion. Thus, ‘proof of concept’ and target validation are necessary before senescence will be seriously
considered as an area for widespread commercial drug discovery.
Progress in this area has been made through the application of cellbased screening approaches [365]. Cell-based assays offer potential
to identify partially validated hits with improved lead-like qualities at the earliest stages of discovery and offer a number of critical
advantages over conventional biochemical screening assays. Puriﬁcation of the target protein in a functional conformation is not
required. Instead, the key requirement is a measurable marker of
endogenous target inhibition such as a change in reporter activity,
protein phosphorylation, or cell morphology. Importantly, cellbased assays may also discriminate between different drug effects,
such as antagonism versus agonism, and identify hits that interact with different target conformations that may be present in
a physiological setting. The characteristic morphological changes
associated with cell senescence including cell enlargement and SA␤Gal activity are suitable for cell based screening approaches using
high content automated imaging. The validity of this approach
has recently been demonstrated in both normal and cancer cellbased screening strategies using siRNA or small molecule libraries
to identify compounds that modulate senescence and targets for
further validation [366,367]. Interestingly, in these studies, senescence occurs in a matter of days post treatment, an advantage over
the longer lag time generally associated with telomerase inhibition.
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Thus senescence is already beginning to show great promise as
an endpoint for drug targeting. Cell-based senescence models and
assays have contributed considerably to advancing new approaches
to drug development. Importantly, a number of agents already
used in the management of human cancers also show associations
with senescence phenotypes, opening up opportunities for drug
re-positioning [80,365]. However, the key questions as to which
patient group will beneﬁt from such agents and clinical trial design
are still open to debate and likely to revolve around the speciﬁc
target in question.
12. Cross-validation
Given the heterogeneity present in most cancers, complete
arrest/eradication of the various subpopulations of cells in any
given cancer will likely require simultaneous targeting of several
molecules and mechanisms that contribute to the malignant phenotype. It is therefore important to anticipate complementary as
well as antagonistic effects on different cancer hallmarks that might
be achieved using agents directed against speciﬁc targets. Accordingly, a literature search has been conducted by a “cross-validation”
team to identify potential consequences of the use of selected
agents targeting protein complexes involved in the maintenance of
replicative immortality on other hallmarks of cancer. The results of
this survey are listed in Table 2. The table indicates that not all interactions are favorable; some agents efﬁcacious against replicative
immortality may exacerbate other hallmarks (e.g., genetic instability), and their utility may be context-dependent.
13. Conclusions
Developing optimized and truly holistic cancer prevention and
treatment regimens will likely incorporate strategies that target
replicative immortality. The chief advantage to be gained by the
use of these senescence-inducing regimens is elimination of tumor
repopulating ability with reduced collateral damage compared to
conventional cytotoxic regimens. There are certain questions and
risks associated with this strategy that must be addressed before
its wholesale adoption in clinical settings. In the case of telomere and telomerase based strategies, replicative senescence may
occur more readily in cancer cells bearing short telomeres than
in vital normal cells with long telomeres, but telomere lengths in
cancer cells may still be long enough to permit sufﬁcient population doublings for invasion and metastases to occur. Moreover,
telomere dysfunction promotes the development of chromosomal
instability, which in turn can generate mutations that enable cells
to become drug resistant and/or activate ALT mechanisms for
telomere maintenance and/or become more malignant. High priority should be given to further research into the determinants of
senescence stability, as the implications of delayed cell cycle
re-entry, permanent cytostasis, or eventual clearance may be profoundly different. Lower doses of genotoxic drugs needed to induce
senescence may reduce collateral damage, but allow establishment
of dormancy by resistant cells. Conversely, since it is almost impossible to kill all the cells in a tumor even at the highest tolerated
doses of chemotherapy, addition of a complementary agent that
induces or enhances stable senescence in the cancer cells that manage to retain viability might additively or synergistically increase
therapeutic efﬁcacy. The microenvironmental and systemic effects
of senescent cells also need further clariﬁcation. While senescent
cells have been shown to secrete proteins that aid in their own
clearance and tissue repair, persistent senescent cells can disrupt niches, causing the depletion of healthy stem cells, and can
promote aging and cancerous phenotypes in surrounding tissues.
Given that some senescence-associated secretory phenotypes can
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be pro-tumorigenic, is senescence still a good objective? Can a
proper immune response be counted on to clear senescent cells?
Ultimately, given the hypermutability and heterogeneity of most
human cancers, it is often unlikely that targeting any single gene
product or pathway will provide lasting remission. However, developing agents with good mechanistic understanding, that effectively
disrupt replicative immortality, may well add to the arsenal available for combinatorial approaches.
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